Arcutis Biotherapeutics (ARQT) News Today → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free ARQT Stock Alerts $7.97 -0.66 (-7.65%) (As of 12:33 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 17 at 1:25 AM | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Up 11.1% in MayArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) saw a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 24,640,000 shares, an increase of 11.1% from the May 15th total of 22,170,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the days-to-cover ratio is currently 7.7 days.June 16 at 6:02 AM | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 8.1%June 15 at 6:14 AM | americanbankingnews.comTraders Purchase Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT)June 15 at 5:31 AM | marketbeat.comOpaleye Management Inc. Makes New $6.33 Million Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Opaleye Management Inc. acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,960,000 shares of the company's stock, vJune 13, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.6% Higher Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.6%June 13, 2024 | marketbeat.comArcutis Biotherapeutics Target of Unusually High Options Trading (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors bought 10,057 call options on the company. This represents an increase of 307% compared to the average volume of 2,472 call options.June 13, 2024 | investorplace.comHave $5-10? 7 Affordable Stocks That Are About to Breakout.June 12, 2024 | marketbeat.comADAR1 Capital Management LLC Buys New Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)ADAR1 Capital Management LLC purchased a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 275,000 shares of the company's stock, valued at approxJune 11, 2024 | marketbeat.comPennant Investors LP Takes $552,000 Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Pennant Investors LP bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 170,900 shares of the companJune 10, 2024 | globenewswire.comArcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema ConferenceJune 10, 2024 | americanbankingnews.comFinancial Review: Arcutis Biotherapeutics (NASDAQ:ARQT) & Galecto (NASDAQ:GLTO)June 9, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is Pivotal bioVenture Partners Investment Advisor LLC's 7th Largest PositionPivotal bioVenture Partners Investment Advisor LLC increased its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 72.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,910,009 shares of the company's stock after purchasingJune 6, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 3.8% Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.8%June 5, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2024 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 23,000 Shares of StockMay 31, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 23,000 SharesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 23,000 shares of the business's stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $8.75, for a total transaction of $201,250.00. Following the completion of the transaction, the insider now directly owns 209,793 shares of the company's stock, valued at approximately $1,835,688.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.May 31, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.2% Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 6.2%May 30, 2024 | insidertrades.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $15,992.75 in StockMay 29, 2024 | marketbeat.comFranklin Resources Inc. Grows Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Franklin Resources Inc. grew its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 260.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,655,544 shares of the coMay 25, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating onMay 24, 2024 | finance.yahoo.comAnalysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This WeekMay 23, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%May 23, 2024 | marketbeat.comGW&K Investment Management LLC Lowers Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)GW&K Investment Management LLC lessened its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 20.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,640,325 shares of the company's sMay 22, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading 3.7% Higher Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 3.7%May 21, 2024 | insidertrades.comLarry Todd Edwards Sells 7,640 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockMay 20, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Larry Todd Edwards Sells 7,640 SharesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) SVP Larry Todd Edwards sold 7,640 shares of the business's stock in a transaction on Friday, May 17th. The shares were sold at an average price of $8.98, for a total transaction of $68,607.20. Following the transaction, the senior vice president now directly owns 140,360 shares in the company, valued at $1,260,432.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.May 20, 2024 | seekingalpha.comArcutis Stock: Sales Expansion Momentum Puts It On A Good TrajectoryMay 16, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.8%Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.8%May 16, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Significant Increase in Short InterestArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 21,690,000 shares, a growth of 10.3% from the April 15th total of 19,660,000 shares. Based on an average daily volume of 3,810,000 shares, the short-interest ratio is currently 5.7 days.May 15, 2024 | markets.businessinsider.comUpgraded Buy Rating and Price Target for Arcutis Biotherapeutics Amid Zoryve’s Robust Sales PerformanceMay 15, 2024 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comQ1 2024 Arcutis Biotherapeutics Inc Earnings CallMay 15, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Announces Earnings Results, Beats Estimates By $0.28 EPSArcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.28. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative return on equity of 294.85%. The company had revenue of $49.57 million during the quarter. During the same period in the prior year, the firm posted ($1.31) earnings per share.May 15, 2024 | marketbeat.comNeedham & Company LLC Raises Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00Needham & Company LLC raised their target price on Arcutis Biotherapeutics from $16.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday.May 15, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up on Analyst UpgradeArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up Following Analyst UpgradeMay 15, 2024 | markets.businessinsider.comA Balanced Outlook: Maintaining Hold on Arcutis Amidst Zoryve’s Mixed Performance and Potential Growth CatalystsMay 15, 2024 | finance.yahoo.comArcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 14, 2024 | msn.comArcutis Biotherapeutics Stock Climbs After Blockbuster Q1 ResultsMay 14, 2024 | investorplace.comARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | markets.businessinsider.comArcutis Biotherapeutics: Strong Prescription Growth Fuels Buy RatingMay 14, 2024 | globenewswire.comArcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | msn.comArcutis Biotherapeutics Q1 2024 Earnings PreviewMay 13, 2024 | globenewswire.comExpert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyMay 11, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases Shares of 194,461 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Los Angeles Capital Management LLC purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 194,461 shMay 10, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4%Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4%May 7, 2024 | marketbeat.comArcutis Biotherapeutics (ARQT) Set to Announce Earnings on TuesdayArcutis Biotherapeutics (NASDAQ:ARQT) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591309)May 4, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.7% Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 6.7%May 3, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.9%Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.9% Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Massive Crisis Looming — Protect Your Savings Now (Ad)Today, Dr. Weiss is coming forward with a new warning, Only this time, it's not about the stock market, inflation, or recession … This time, it's about your financial freedom. Click here to learn how to prepare before it's too late. ARQT Media Mentions By Week ARQT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.740.92▲Average Medical News Sentiment ARQT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼135▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OCUL News Today INVA News Today PHAT News Today ORIC News Today NKTX News Today KNSA News Today SUPN News Today KPTI News Today BTAI News Today PBH News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | Sponsored